Pharmaceuticals

Gilead: Cultivating the Pipeline

April 24, 2017 / by Jason Cheung and Dennis Zhan / 0 Comment

In order to restore investor confidence and hedge legacy market downturns, Gilead needs to diversify into other channels of sustainable revenue generation to minimize volatility


0

The Biosimilar Onslaught

January 05, 2016 / by Kevin Shi and Nawid Sayed / 0 Comment

Pharmaceutical companies face huge revenue uncertainties after the loss of patent exclusivity; but not all is lost.